UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 000-55857 LIFEMD, INC. (Exact name of registrant as specified in its charter) | Delaware | 76-0238453 | | --- | --- | ...

LifeMD, Inc. (NASDAQ:LFMD) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Justin Schreiber - President & Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Andrew D'Silva - B. Riley Securities Operator Good afternoon. Thank you for joining us today to discuss the results for LifeMD's Second Quarter of 2021 Ended June, 30, 2021. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 000-55857 LIFEMD, INC. (Exact name of registrant as specified in its charter) (State or other Jurisdiction of Incorporation ...

LifeMD, Inc. (NASDAQ:LFMD) Q1 2021 Results Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Justin Schreiber - President & Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Andrew D'Silva - B. Riley Securities Operator Good afternoon. Thank you for joining us today to discuss LifeMD’s First Quarter Fiscal 2021 Results for the three months ended March 31, 2021. Joining us today is the Chairman and Chief Executive Officer of L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 000-55857 LIFEMD, INC. (Exact name of registrant as specified in its charter) (State or other Jurisdiction of Incorpor ...

LifeMD: Radically Changing Healthcare with State-of-the-Art Direct-to-Consumer Telemedicine April 2021 NASDAQ : LFMD Important Cautions Regarding Forward-Looking Statements NASDAQ:LFMD Statements in this presentation that are not descriptions of historical facts are forward-looking statements relating to future events, and as such all forward-looking statements are made pursuant to the Securities Litigation Reform Act of 1995. Statements may contain certain forward-looking statements pertaining to future an ...

LifeMD, Inc. (NASDAQ:LFMD) Q4 2020 Earnings Conference Call March 29, 2021 4:30 PM ET Company Participants Justin Schreiber - CEO Marc Benathen - CFO Conference Call Participants David Larsen - BTIG Andrew D'Silva - B. Riley Securities Operator Good afternoon. Thank you for joining us today to discuss LifeMD’s Fourth Quarter and Full-Year 2020 Results ended December 31, 2020. Joining us today is the Chief Executive Officer of LifeMD, Justin Schreiber; and Company's Chief Financial Officer, Marc Benathen. Fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________________ to __________________________ Commission file number 000-55857 LIFEMD, INC. (Exact name of registrant as specified in its charter) CONVERSI ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------|-------|-------|-------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Radically Changing Healthcare | | | | | | | | | | | | with State-of-the-Art Direct-to-Consumer Telemedicine | | | | | | | | | | | | | | | | | | | | | | | Important Cautions Regarding Forward-Looking Statements 2 NA ...

Conversion Labs, Inc. (CVLB) Q3 2020 Earnings Conference Call November 16, 2020 4:30 PM ET Company Participants Justin Schreiber – Chief Executive Officer Juan Piñeiro – Chief Financial Officer Stefan Galluppi – Chief Marketing Officer Conference Call Participants Andrew DeSilva – B. Riley Securities Corey Deutsch – Paradigm Opportunities, LLC John DeMaio – Newbridge Securities Operator Good afternoon. Thank you for joining us today to discuss Conversion Labs Third Quarter Results Ended September 30, 2020. ...